Fundraising Fox
Broadview Ventures
Venture capitalBoston · Seed–Series A · 21 people tracked
Find your way into Broadview Ventures
Each arrow is one introduction. Sign up to fill in the first one.
Ask Joachim Vogt to introduce you to Thomas Needham
You →Joachim · together at GPC Biotech →Thomas
Ask Jamie Chen to introduce you to Daniel Gottlieb
You →Jamie · together at Nyra Medical →Daniel
Ask Sam Okafor to introduce you to Ian Meredith
You →Sam · together at Anumana →Ian
- Benjamin Kreitman249 people can intro you
- Hewmun Lau228 people can intro you
- Christopher de Souza174 people can intro you
Sign up to find every way you can get introduced to Broadview Ventures
- Your email: who you already know at Broadview Ventures, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Broadview Ventures team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Broadview Ventures pursues impact investing in the cardiovascular disease space. Its mission is to accelerate the development of promising technologies for diagnosing and treating cardiovascular disease and stroke, aiming to get new treatments to patients. The firm makes targeted investments and maintains a diversified portfolio across a range of relevant technologies.
Source: firm website, verified Sep 27, 2026.
Team · 21 people
from the firm's website & public directories
What they invest in
from 52 of 73 portfolio companiesHealthtech ×41Medical Devices ×35Biotech ×30Digital Health ×11Hardware ×8AI & Machine Learning ×6Deep Tech ×5FemTech ×1
HQs:United States×30Denmark×2Switzerland×1Finland×1France×1United Kingdom×1
Who they back
founder profiles across 26 portfolio companiesFounding team size:solo founder×132 founders×73 founders×14+ founders×5
Where their founders studiedfrom 21 founders with education data
École de technologie supérieure ×3Case Western Reserve University ×2Københavns Universitet - University of Copenhagen ×2
What their founders studiedfrom 20 founders with field-of-study data
Engineering ×8Life Sciences ×5Medicine ×4Business & Management ×2
Where their founders worked beforefrom 24 founders with career history
CHUV | Lausanne university hospital ×2Columbia University Medical Center ×2Deerfield Catalyst ×2
8 founders hold a PhD · 4 hold an MBA (of 22 with degree data)
Investments · 73 tracked
founders shown can be your intro pathBy year:2024 · 32022 · 42020 · 42019 · 12017 · 32016 · 32015 · 62014 · 32013 · 22012 · 534 dated
Capricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy.
BiotechMedical DevicesLos Angeles, US
Linda Marban(President and Chief Executive Officer, Director)inLinda Marbán, Ph.D.(Chief Executive Officer and Director; co-founder of Capricor, Inc.)Rachel Smith(Executive Officer)inKaren Krasney(Executive Officer)inAnthony Bergmann(Executive Officer)Andrew Hamer(Executive Officer)in
miRagen Therapeutics is a biopharmaceutical company developing monoclonal antibodies and other engineered protein therapeutics targeting specific receptors (IGF-1R, FcRn, and TSHR) for autoimmune and rare diseases including thyroid eye disease, Graves' disease, and various autoimmune conditions.
BiotechBoulder, US
William S. Marshall(Executive Officer, Director)Jason A. Leverone(Executive Officer)inDavid Rodman(Executive Officer)Stephen Mahoney(President, Chief Executive Officer and Director)Thomas Beetham(Chief Operating Officer)inRadhika Tripuraneni(Chief Medical Officer)in
Co-investorsBrace PharmaMC Healthcare VenturesRidgeback CapitalAtlas VentureBoulder VenturesHeartland+1 more
Aeromics is a clinical-stage pharmaceutical company developing AER-271, an intravenous aquaporin-4 (AQP4) inhibitor designed to prevent cerebral edema (brain swelling) following severe, acute ischemic stroke.
BiotechHealthtechNew Haven, US
Dr. Pelletier(Co-founder)Dr. Boron(Founder)Marc Pelletier(Manager, Chief Executive Officer)William Boron(Co-founder)Paul McGuirk(Executive Officer)George Farr(Executive Officer)
Co-investorsConnecticut Innovations
Corflow develops diagnostic and therapeutic solutions to restore healthy microvascular blood flow in the human body, serving the cardiovascular medical device industry.
HardwareHealthtechMedical Devices
Martin(Physician Co-Founder)Rick Geoffrion(Chairman and CEO)
Co-investors415 CapitalLaerdal Million Lives FundPanakes PartnersKorysMérieux Equity PartnersMonte Carlo Capital+1 more
HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease.
AI & Machine LearningBiotechDeep TechHealthtech
Samir Ounzain(Chief Executive Officer (CEO) & Co-founder)inDaniel Blessing(Chief Scientific Officer (CSO) & Co-founder)inRichard Law(Chief Business Officer (CBO))inEric Adam(Chief Operating Officer (COO))inJordan Shin(Chief Medical Officer (CMO))inJérôme Andries(Chief Financial Officer (CFO))in
Co-investorsSofinnova PartnersApollo Health Ventures+ND Capital4see VenturesLifelinkHumboldt
Nyra Medical develops the CARLEN (Cardiac Leaflet Enhancer) system, a transcatheter single-leaflet device for repairing functional mitral regurgitation while preserving native valve function.
BiotechHealthtechMedical DevicesAtlanta, US
Dr. Murali Padala(Founder)Dr. Eric Sarin(Founder, Director)Dr. Kirthana Suresh(Founder)Sai Muralidhar Padala(Executive Officer, Director)Lori Chmura(CEO)inGowri Raman(Director)
Co-investorsEpidarex CapitalVensana CapitalGRA Venture
Puzzle Medical develops a heart failure treatment device designed to improve heart and kidney function through 4Fr axillary access, allowing patient ambulation and providing up to seven days of support.
HardwareHealthtechMedical DevicesMontreal
Jade Doucet-Martineau(Co-founder & CEO, Board Director)inFrançois Trudeau(Co-founder & CTO, Board Director)inPhilippe Généreux(Co-founder (Phase 2), Chief Medical Officer & Board Observer)inMaxime Rochon(Co-founder (Phase 2) & VP Clinical, Regulatory and Quality)inYves-Antoine Crête(Co-founder (Phase 2) & VP Technical R&D and Operations)inGabriel Georges(Co-founder & Clinical Advisor)in
Co-investorsLumira VenturesAjax HealthDesjardins CapitalBoreal VenturesCathexis VenturesFront Row Ventures+3 more
Relief Cardiovascular develops transcatheter smart implant systems for volume management in congestive heart failure, including the Relief System, a preload-modulating implant for inferior vena cava flow modulation with autonomous hemodynamic monitoring.
BiotechHealthtechMedical DevicesCosta Mesa, US
Co-investorsAdvent Life SciencesGood Growth CapitalVensana Capital
Acesion Pharma is a biotech company developing pharmaceutical treatments.
BiotechHealthtechMedical DevicesCopenhagen, DK
Ulrik Sørensen(COO & Co-founder)inMorten Grunnet(CSO & Co-founder)inAnders Gaarsdal Holst(CEO & CMO)inTorgeir Vaage(CFO)in
Co-investorsAlpha Wave GlobalCanaan PartnersNovo HoldingsGlobal BioAccess Fund
Adient Medical develops absorbable medical devices, including implants designed to remain safe and effective during their useful lifetime and then dissolve on their own, avoiding removal procedures and related complications.
BiotechHealthtechMedical DevicesPearland, US
Mitchell Eggers(Executive Officer, Director)
BoardMichael Hogan(Director)Robert Tucci(Director)in
Co-investorsGrant Park VenturesHouston Angel NetworkTexas HALO FundTexas Ventures
Alleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).
BiotechHealthtechMedical DevicesAustin, US
Adam Berman(Executive Officer, Director)inJacob Kriegel(Executive Officer, Director)Avni Patel(Executive Officer, Director)Christopher Alex Arevalos(Executive Officer, Director)Albertien Greijdanus(Executive Officer, Director)
BoardGeoff Pardo(Director)in
Co-investorsRiverVest Venture PartnersTMC Venture FundCadence Healthcare VenturesGilde HealthcareGilmartin Capital LLCOmega Funds+2 more
Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients.
BiotechHealthtechCopenhagen, DK
Jens Juul Holst(Founder)Mette Rosenkilde(Founder)in
Co-investorsNovo HoldingsSR One Capital ManagementVersant Ventures
HealthtechCampbell, US
Amr Salahieh(Executive Officer, Director)inMotasim Sirhan(Director)
BoardTara Butler, M.D.(Director)Rob Kuhling(Director)Henry Chen(Director)Greg Casciaro(Director)
Co-investorsAscension Ventures
BiotechHealthtechSt. Paul, US
Joshua Woolley(Executive Officer)inRyan Gladney(Executive Officer)Gary Graham(Executive Officer)Dan W. Gladney(Executive Officer, Director)inPeter DeLange(Executive Officer)inBruce A. Machmeier(Executive Officer)
Co-investorsAngel Physicians FundBrightstone Venture CapitalCatalyst Health VenturesPortfoliaXeraya CapitalBioStar Ventures
Ascension Ventures is a healthcare venture capital fund and innovation catalyst managing over $1 billion in capital that invests in emerging healthcare innovators and technologies.
HealthtechSector Agnostic
Co-investorsOSF Ventures
AtaCor Medical develops extravascular lead systems for cardiac rhythm management, including a novel extravascular defibrillation lead for EV-ICD therapy and an implantable, extracardiac pacemaker.
HardwareHealthtechMedical Devices
Alan(Co-founder & Vice President of Clinical, Regulatory & Quality)
Co-investorsArboretum VenturesBayMed Venture PartnersCatalyst Health VenturesHatteras Venture Partners
Basking Biosciences develops therapeutics for thrombosis, vascular biology, and ischemic disease.
BiotechDigital HealthHealthtechMedical DevicesCary, US
Shahid Nimjee(Co-founder, Chief Scientific Officer and Stroke Clinical Lead)inBruce Sullenger(Co-founder)Julia Owens(Executive Officer, Director, Promoter)inRichard Shea(Executive Officer, Director, Promoter)in
BoardHannah Chang(Director)Aiden Aceves(Director)in
Co-investorsARCH Venture PartnersInsight PartnersMedblueSolas BioVenturesPlatanus VenturesRev1 Ventures+1 more
BioKier develops oral products for managing lipids and glucose in type 2 diabetes and cardiometabolic disorders, designed to replicate the metabolic benefits of bariatric surgery through colon-targeted nutrient delivery.
BiotechHealthtechMedical DevicesChapel Hill, US
Jerzy R Szewczyk(Executive Officer, Director)Roger D Nolan(Executive Officer, Director)in
BoardJames Farrelly(Director)
Co-investorsFreemind Investments
Developing implantable low-energy pain-free atrial cardioverters for atrial fibrillation.
HealthtechSt. Louis, US
M. Brent Shelton(Executive Officer)Paula Skjefte(Executive Officer, Director)Nick Lanners(Executive Officer)Igor Efimov(Director)
BoardEric A. Gulve(Executive Officer, Director)Warren Watson(Director)
Co-investorsRiverVest Venture PartnersCultivation Capital
Cardiosense develops wearable sensing hardware and deep-learning algorithms that convert physiological signals into clinical insights for cardiovascular disease detection and management.
AI & Machine LearningDigital HealthHealthtechMedical DevicesChicago, US
Amit Gupta(Co-founder, Advisor)inMozziyar Etemadi(Co-founder, Head of AI)Omer Inan(Co-founder, Chief Scientific Officer)inAndrew Carek(Co-founder, Chief Technical Officer)inEric Meizlish(Chief Executive Officer)inJohn D. Martin(Chief Medical Officer)in
Co-investorsBayMed Venture PartnersCross-Border Impact VenturesLaerdal Million Lives FundOSF VenturesPortal InnovationsArboretum Ventures+1 more
Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women.
BiotechFemTechHealthtechConcord, US
Mike Young(Founder)inT Scott Johnson(Founder)inPaul Antinori(Executive Officer)Allison August(Executive Officer)inThomas Scott Johnson(Executive Officer, Director)
BoardBrendan Bulik-Sullivan(Director)in
Co-investorsAtlas VentureGV (Google Ventures)F-Prime CapitalLilly Asia VenturesNew Enterprise Associates (NEA)
Coridea invests in and develops healthcare companies focused on patient-centric solutions.
HealthtechMedical Devices
Mark Gelfand(Managing Partner and Chief Technical Officer)inHoward R. Levin(Managing Partner, President, and Chief Medical Officer)inZoar Engelman(Partner and Chief Scientific Officer)inAdam Rosenwach(Partner and Chief Business Officer)in
Co-investorsStar51 Capital
CroíValve develops the DUO System, a minimally invasive heart valve device designed to treat tricuspid regurgitation, a common and often underdiagnosed heart condition.
HealthtechMedical Devices
Dr. Martin Quinn(Co-Founder)
Co-investorsAtlantic Bridge VenturesFurthr VC
Epirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy.
BiotechMedical DevicesSan Diego, US
Pam Taub(M.D., FACC, Founder)Alan Maisel(M.D., Founder)Francisco Villarreal(M.D., Ph.D., Founder)Jonathan Taub(Co-founder and first Chief Executive Officer)Guillermo Ceballos(M.D., Founding Scientist)Pam Taub, M.D., FACC(Co-founder)
Co-investorsBluebird VenturesLongitude CapitalAdams Street PartnersARCH Venture PartnersVertex VenturesVertex Ventures HC
FineHeart develops the FlowMaker®, a wirelessly powered, fully implantable mechanical circulatory support device designed to optimize cardiac output for patients with severe heart failure.
AI & Machine LearningDeep TechHealthtechMedical DevicesBordeaux, FR
Arnaud Mascarell(CEO)inDr. Stephane Garrigue(Founder, Inventor)Dr. Philippe Ritter(Co-founder)
Co-investorsAQUITI GestionM Capital Partners
Gila Therapeutics is a clinical-stage biotech company developing a topical lingual signaling platform that delivers micro-dose PYY dissolving on the tongue to activate brain regions regulating food intake and metabolism.
BiotechDigital HealthHealthtechLongevityMinneapolis, US
Jon Freeman(Executive Officer)Donald R. Johns(Chief Medical Officer)Thomas J. Vasicek(Executive Officer, Director, Promoter)
BoardChristopher de Souza(Director)inRichard Horan(Director)
Co-investorsArgonautic VenturesHarvard Business Angels of ChicagoiSelect FundElephant Partners
Herantis Pharma is a public pharmaceutical company listed on Nasdaq First North Growth Market Finland, focused on developing therapeutic treatments.
BiotechDeep TechMedical Devices
Antti Vuolanto(CEO)in
Co-investorsInnovestor Ventures
i3 develops a hybrid intravascular imaging catheter combining near-infrared fluorescence (NIRF) and ultrasound (IVUS) sensors to provide real-time molecular and structural imaging during coronary interventions.
AI & Machine LearningDeep TechHealthtechMedical DevicesBoston, US
InfoBionic.Ai develops a remote cardiac monitoring platform called MoMe ARC that combines AI-powered ECG analysis, interchangeable biosensors, and clinical analytics to enable hospital-grade cardiac telemetry outside traditional hospital settings.
AI & Machine LearningHealthtechMedical DevicesLowell, US
Steven Wasserman(Executive Officer)Nancy Briefs(Executive Officer, Director)
BoardCarl Berke(Director)Caleb Winder(Director)inAl Wiegman(Director)Hamid Tabatabaie(Director)
Co-investorsExcel Venture ManagementHealthtech CapitalKeiretsu Forum
JICRM is an open-access, peer-reviewed clinical journal published 12 times annually that disseminates research on cardiac electrophysiology and arrhythmia management for electrophysiologists and healthcare professionals.
HealthtechMedia & EntertainmentMedical DevicesJonesboro, US
Devi G. Nair(Editor-in-Chief)
Ischemia Care operates a CLIA-certified laboratory that develops blood tests for stroke patients using RNA expression analysis to determine stroke cause and improve clinical outcomes.
AI & Machine LearningDigital HealthHealthtechMedical DevicesOxford, US
Jeffrey June(Executive Officer, Director)Teresa June(Executive Officer)in
Co-investorsSolas BioVenturesEarly Stage Partners, LP
Lyra Therapeutics develops biocompatible mesh scaffolds for sustained drug delivery to the sinonasal passages, targeting treatment of chronic rhinosinusitis.
BiotechHealthtechMedical Devices
Maxwell Biomedical develops a device-based alternative to catheter ablation for atrial fibrillation, using closed-loop adaptive left atrial multisite pacing and Spatial Resynchronization Therapy (SRT) to terminate AF without high-energy shock.
BiotechHardwareHealthtechMedical Devices
Randy Werneth(CEO, President)inTimothy Corvi(Sr. VP, R&D)inDerrick Chou(VP, Science & Technology)
Co-investorsRiverVest Venture Partners
Boston-based developer of an in vitro diagnostic test for diabetes based on the glycated CD59 (GCD59) biomarker.
BiotechBoston, US
Jose Halperin(Director)inJoyce Lonergan(Executive Officer)Michael Chorev(Director)
Co-investorsDreamers VCElephant Partners
Mellitus Health develops FDA-cleared decision-support software that helps clinicians optimize insulin dosing for diabetes patients by analyzing glucometer readings and providing patient-specific dosage adjustments.
Digital HealthHealthtechMedical DevicesSaaS
Steven Yecies
BoardMayer B. Davidson(MD, former American Diabetes Association president)
Co-investorsOpen Field Capital
Mosanna is a pharmaceutical company developing a non-invasive nasal spray therapy for obstructive sleep apnea (OSA) that reactivates the body's natural airway reflex to keep the upper airway open during sleep.
BiotechDigital HealthHealthtechMedical Devices
Barbara(Regulatory Affairs & Quality Assurance leadership)Kevin(Pharmaceutical Development leadership)Pranav(Head of Finance & Operations)Ben(Executive / Board)
BoardDavid White(Sleep Medicine Advisor)
Co-investorsNorwest Venture PartnersPivotal Life SciencesSupermoon CapitalHTGFInkef
NuPulse develops a cardiac support device used as a bridge to heart transplant, helping patients maintain mobility and improve their condition while awaiting a donor heart.
HardwareHealthtechMedical Devices
NuPulseCV develops the Voyage device, a cardiac support technology aimed at patients with heart failure who are treated at both major institutions and community hospitals.
BiotechHardwareHealthtechMedical DevicesRaleigh, US
VALLUVAN JEEVANANDAM(Director)GREG SCOTT(Director)RICHARD SHERMAN(Director)ALEX SHLYANKEVICH(Director)SONNA PATEL-RAMAN(Executive Officer)DOUGLAS ALTSCHULER(Executive Officer, Director)
RapidPulse Medical is an investor relations page showcasing multiple healthcare-focused investment firms and incubators that back medical device and healthcare technology companies.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsEpidarex CapitalFlorida Opportunity FundHatteras Venture PartnersS3 VenturesSante Ventures
Remedy Pharmaceuticals is a pharmaceutical company developing Cirara, an investigational drug studied in clinical trials for patients who have suffered a stroke.
BiotechHealthtechNew York, US
SVEN JACOBSON(Executive Officer, Director)
BoardDAVID GELIEBTER(Director)
Co-investorsThe Vertical Group
BiotechGreenwhich, US
Wendy DiCicco(Ms. DiCicco is the Secretary and Treasurer of the Issuer.)inArthur Feldman(Director)Magdalene Cook(Executive Officer, Director)Campbell Murray(Director)Edward J. Benz, Jr.(Director)Thomas Needham(Director)in
Co-investorsBioAdvanceElysia CapitalInnogest CapitalNew Leaf Venture PartnersNovartis Venture Fund
Rocket Pharmaceuticals develops gene therapies to treat patients with rare genetic diseases, focusing on cardiovascular and hematologic disorders.
BiotechDigital HealthMedical Devices
Gaurav Shah(Co-founder & Chief Executive Officer)in
BoardRoderick Wong(Director)inNaveen Yalamanchi(Director)in
Co-investorsAvoro Capital AdvisorsCivilization Ventures Management, LlcFrazier Life SciencesLifeSci Venture PartnersRTW Investments L.P.
Vascular Graft Solutions develops medical device technologies for coronary revascularization procedures, with a focus on addressing vein graft disease in cardiac bypass surgery.
HardwareHealthtechMedical Devices
Eyal Orion(Founder & Active Chairman)in
Co-investorsGEOCPontifax Venture CapitalTal Ventures
Vectorious Medical Technologies develops implantable sensing platforms designed to deliver clinical information for patient therapies.
Digital HealthHardwareHealthtechMedical Devices
Co-investorsChampel CapitalFresenius Medical Care VenturesGEOC
Viridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit.
BiotechDigital HealthMedical DevicesWaltham, US
Jonathan Violin(Executive Officer, Director)in
BoardPeter Harwin(Director)Tomas Kiselak(Director)
Co-investorsLongitude CapitalMRL Ventures Fund
XII Medical develops neuromodulation therapies for treating obstructive sleep apnea, focusing on simplifying treatment options and improving patient outcomes.
Deep TechDigital HealthHealthtechMedical DevicesUnion City, US
Garrett Schwab(Chief Executive Officer)inShane Kreidel(Secretary and Chief Financial Officer)inZachary Eisen(Director)
BoardDuke Rohlen(Director)inJD Friedland(Director)Saoussen Ben Halima(Director)
Co-investorsAPERTURE Venture PartnersCincyTechIntuitive VenturesJobsOhio VenturesAjax HealthOmega Funds
ZZ Biotech develops 3K3A-APC, a genetically engineered variant of human activated protein C (a serine protease) optimized for therapeutic use.
BiotechHouston, US
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
480 BiomedicalAggaminAllosteros TherapeuticsAlveron PharmaAlveron PharmaceuticalsCardiAQ Valve TechnologiesCellAegis DevicesCroíValveDecimmuneDecImmune TherapeuticsEP SciencesIntravascular Imaging, Inc.Kantum PharmaLaurantis PharmaMosanna TherapeuticsNIDONido SurgicalProvasculonSyntheon 2.0Vectorious Medical TechnologiesVentriNovaViridian Therapeutics (Formerly MiRagen Therapeutics)Zumbro Discovery
Exits · 3
2 IPOs · 1 acquisitionsCapricor TherapeuticsNASDAQ: CAPRmiRagen TherapeuticsNASDAQ: VRDNCardiAQ Valve Technologiesacq. by Edwards Lifesciences
Portfolio news
latest coverage across their companies
Capricor Therapeutics · biospace.com · Aug 21, 2026
Antag Therapeutics · globenewswire.com · May 21, 2026
Herantis Pharma · biospace.com · Mar 5, 2026
Basking Biosciences · insightpartners.com · Jan 21, 2026
Mosanna · finsmes.com · Jun 9, 2025
Frequently asked questions
- How many investments has Broadview Ventures made?
- Broadview Ventures has 73 tracked investments, 3 of which have exited, including 1 dated in the last 24 months.
- What stage does Broadview Ventures invest at?
- Broadview Ventures invests at the Seed, Series A stages.
- What sectors does Broadview Ventures focus on?
- Broadview Ventures focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Impact & Social Good, Medical Devices.
- Where is Broadview Ventures located?
- Broadview Ventures is headquartered in Boston, US.
- Who does Broadview Ventures co-invest with?
- Broadview Ventures most often shares deals with RiverVest Venture Partners, BayMed Venture Partners, Catalyst Health Ventures, among 90 tracked co-investors.
- What size deals does Broadview Ventures back?
- Across 20 deals with disclosed amounts, Broadview Ventures has joined rounds of $1M – $31M (median $2M).
Images
Co-investors · 10
Hatteras Venture Partners is a venture capital firm focused on early-stage life sciences and healthcare companies, backing therapeutics, diagnostics, and businesses aiming to transform healthcare delivery and innovation.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Arboretum Ventures is a Midwest-based venture capital firm focused on the healthcare industry, investing in early-stage companies across medical devices, life science tools and diagnostics, tech-enabled care delivery, and pharma adjacencies.
Advent Life Sciences is a trans-Atlantic venture capital firm investing in early and mid-stage life sciences companies across the UK, Europe and the USA.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
Apollo Health Ventures is a biotech-focused investor that combines traditional funding with venture building to back transformative healthcare and longevity companies in Europe and the US.
Humboldt Fund focuses exclusively on synthetic biology as a general-purpose technology to remake chemicals, materials, foods, and medicines, led by a UCSF-trained PhD cell biologist who brings deep research background directly into fund leadership. The fund backs "bio revolution" companies that replace conventional industrial inputs with biology-based alternatives through a concentrated portfolio of category-defining names like Geltor, NotCo, Meatable, and MycoWorks, while investing globally across Latin America and Europe rather than maintaining a US-centric focus.
BioStar Ventures (BioStar Capital) is a healthcare-focused venture firm whose team combines healthcare executives, venture capitalists, physician inventors, practitioners, and FDA experts to evaluate medical technology investments.
SOSV is a deep tech venture capital firm that makes first-check pre-seed investments and follow-on rounds in startups focused on human and planetary health, providing lab space and hands-on support at its US locations.
Pillar VC is an early-stage venture capital firm that partners with technical founders at the inception stage to build technology companies.
Firms observed investing alongside Broadview Ventures, from public investor directories. Shared companies are the overlap with Broadview Ventures's recorded portfolio.
Similar investors
Future Positive Capital is a venture firm backing entrepreneurs building companies that address large-scale global challenges across health, sustainability and technology.
Lerer Hippeau is an early-stage venture capital firm that backs founders across sectors, emphasizing investing in companies before they gain wider recognition.
MDI Ventures is the corporate venture capital arm of Indonesian telecommunications company Telkom Indonesia, investing in high-growth technology startups across Southeast Asia and globally, with a focus on creating synergies between portfolio companies and Telkom Group and Indonesian state-owned enterprises.
Qbic is an inter-university venture capital fund that backs the transformation of technological breakthroughs from its academic and research partners into sustainable businesses.
LOUD (LOUD Collective / LOUD Ventures) is an alternative investment firm and growth platform that combines capital with hands-on operational support, leadership, and strategy consulting to co-build companies alongside founders.